QPS Holdings

What QPS Holdings does

QPS Holdings, LLC is a privately held, founder-led global contract research organization (CRO) founded in 1995 by Dr. Benjamin Chien, headquartered in Newark, Delaware at the Delaware Technology Park. The company is GLP- and GCP-compliant and provides integrated drug development services spanning bioanalysis, preclinical research, and clinical trial operations for pharmaceutical, biotechnology, and generic drug developer clients.

The technical core of QPS is its bioanalytical platform, anchored by LC-MS/MS instrumentation and a proprietary library of 800+ validated assays covering small molecules, large molecules, and genomic biomarkers, made accessible through the proprietary QPS Assay Finder mobile and web application. Service lines extend into DMPK, toxicology, pharmacology, biotherapeutics, biomarkers and translational medicine, cell and gene therapy, genomics, and ICP-MS elemental analysis, with Phase I-IV clinical operations delivered through dedicated early-phase units in Miami (110 beds) and Missouri (240 beds) plus Phase I-IV operations in Taiwan (Qualitix, NKSP) and India (Hyderabad). Pharmacovigilance runs on the Oracle Argus safety database.

QPS operates nine facilities across the US, Netherlands, Austria, India, and Taiwan, supported by 1,250+ employees and a wholly-owned subsidiary structure. Revenue is generated through project-based CRO contracts priced on study scope, complexity, and regulatory requirements, sold via direct enterprise sales with client-dedicated senior teams rather than portals or project-manager handoffs. Go-to-market relies on scientific thought leadership, conferences, and the Assay Finder tool. The business has grown entirely organically and through tuck-in acquisitions, with the 2025 divestiture of its Neuropharmacology unit to Scantox representing a recent portfolio refocus toward cell and gene therapy, oncology, and obesity (GLP-1) capabilities.

Name

QPS Holdings

Legal name

QPS Holdings, LLC

Website

https://qps.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

QPS Holdings is a privately held, founder-led global CRO founded in 1995 providing GLP/GCP-compliant bioanalytical, preclinical, and Phase I-IV clinical services to pharmaceutical and biotechnology sponsors across nine facilities in the US, Europe, and Asia.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

akta.pro secondary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Bioanalytical CRO services
• Preclinical drug development
• Clinical trial management
• Pharmacovigilance services
• Contract research organization

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: QPS generates revenue through project-based contracts for bioanalytical services, preclinical studies (DMPK, Toxicology, Pharmacology), and clinical trial management (Phase I-IV). Projects are custom-built around individual client program needs with pricing based on study scope, complexity, and timeline requirements. Revenue is recognized as services are delivered across the drug development continuum.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

QPS Holdings is a GLP/GCP/CLIA-compliant contract research organization that provides integrated bioanalytical services, preclinical research (DMPK, Toxicology, Pharmacology), and clinical trial management (Phase I-IV) to pharmaceutical and biotechnology companies. Services span small and large molecule bioanalysis, gene and cell therapy support, biomarkers, translational medicine, pharmacovigilance, and regulatory submission support across global jurisdictions. The company operates nine facilities across North America, Europe, and Asia and has completed thousands of studies since 1995.

Product overview

QPS Holdings is a global full-service Contract Research Organization (CRO) founded in 1995, offering integrated preclinical and clinical research services. The company's portfolio spans bioanalytical services (LC-MS/MS, LBA, hybrid LC-MS/MS), preclinical studies (DMPK, Toxicology, Pharmacology, Biotransformation, Drug-Drug Interaction, Protein Binding, Radiolabeled ADME), and clinical trial services (Phase I-IV units in USA, Taiwan, and India). Key products include the QPS Assay Finder (800+ validated assays searchable via web/app), Biomarkers & Translational Medicine, Biotherapeutics, Cell and Gene Therapy, Genomics, and CLIA-certified laboratory services. The company operates 9 facilities across 6 global regions and leverages Oracle Argus for pharmacovigilance.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioanalysis Services Full range of bioanalytical services supporting drug development from discovery through clinical development and regulatory filing, including small molecules, protein biotherapeutics, vaccines, gene therapy, and cell therapy quantitation using LC-MS/MS, LBA, and hybrid platforms. For pharmaceutical and biotechnology companies.
• Preclinical Services Comprehensive preclinical CRO services spanning DMPK (ADME characterization, radiolabeled studies, QWBA), Toxicology (standard toxicology protocols across multiple species), and Pharmacology (validated disease models). For pharmaceutical and biotechnology companies.
• Clinical Trial Services - Phase I-IV Phase I-IV clinical trial services spanning early stage clinical trials (SAD/MAD, BE/BA, PK/PD, food effects, vaccine trials, special populations) through multinational Phase II-IV clinical research, including site identification, project management, monitoring, medical writing, biostatistics, data management, and real-world evidence studies. For pharmaceutical and biotechnology companies.
• Pharmacovigilance Services Drug safety case management services powered by Oracle Argus, providing patient safety oversight, adverse event capture, regulatory reporting, and operational efficiency across global clinical programs. For pharmaceutical and biotechnology companies.
• CLIA-certified Laboratory Services CLIA high complexity testing certified in 49 states supporting diagnostic tests for clinical trial inclusion/exclusion, stratification, and Phase IV adverse effects evaluation. For pharmaceutical and biotechnology companies.
• QPS Assay Finder Industry tool containing a proprietary library of over 800 validated bioanalytical assays for small molecule, large molecule, and genomic biomarker studies, available as iOS, Android, and web applications. Used by pharmaceutical and biotechnology procurement teams to identify assays for bioanalytical studies.

Quantifiable outcome

• 40%+ of Qualitix studies are oncology trials since 2015
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature8 records

Partnerships

One partnership is on record.

• OraclecoreTechnology or Integration · 16 January 2026QPS implemented Oracle Argus, a pharmacovigilance system for drug safety case management in clinical trials. The platform enables adverse event capture, management, and regulatory reporting in compliance with global regulatory requirements.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Large global CRO/CDMO with deep preclinical and bioanalytical capabilities, including safety assessment, DMPK, and biologics — directly overlapping with QPS's preclinical and bioanalysis franchises but operating at much greater scale.
• ICON plc: One of the largest global CROs offering full-service clinical development, bioanalytical, and post-approval services; overlaps significantly with QPS's Phase IIb-IV clinical operations though at meaningfully larger scale.
• IQVIA: Largest global CRO/clinical services provider with extensive bioanalytical, clinical, and real-world evidence capabilities; competes with QPS in nearly every service line but at vastly greater scale and preferred-provider market share.
• WuXi AppTec: Global CRO/CDMO offering preclinical, clinical, bioanalytical, and biologics services; comparable in service breadth and global footprint to QPS, with particularly overlapping preclinical DMPK and toxicology franchises.
• Fortrea (Labcorp spinoff): Clinical CRO spun out of Labcorp in 2023 covering Phase I-IV clinical development, bioanalysis, and post-approval services — a broad-incumbent competitor to QPS's clinical operations business.

Direct peers

• Medpace Holdings: Mid-size, founder-influenced clinical CRO focused on Phase I-IV trials across multiple therapeutic areas; comparable size and operating philosophy to QPS's clinical services business, with similar emphasis on scientific credibility and dedicated teams.
• Worldwide Clinical Trials: Privately held mid-size global CRO with bioanalytical, early-phase clinical, and therapeutic area expertise — a closely comparable peer in scale, business model, and service mix to QPS.
• Syneos Health: Full-service clinical and commercial CRO with comparable Phase I-IV, bioanalytical, and consulting offerings — competes with QPS for mid-tier pharma and biotech sponsors across multiple therapeutic areas.
• Frontage Laboratories: Mid-size CRO with strong bioanalytical, CMC, and clinical services — particularly comparable to QPS in small molecule and biologics bioanalysis, with overlapping client base among generic and innovative drug developers.
• Biotrial: European-headquartered clinical CRO specializing in early-phase trials and neuroscience — closely comparable to QPS Austria's neurology center of excellence and Phase I clinical capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCp9LTaQcd8WAb1__F6stp4w/videos
• Facebookfacebook.com/QPS.LLC
• LinkedInlinkedin.com/company/428315
• Xx.com/qpsholdingsllc

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QPS Holdings